Based on the GENIE Consortium Project, what percentage of patients is estimated to be eligible for targeted therapy within the framework of precision cancer medicine, when evaluated with NGS?

Based on the GENIE Consortium Project, what percentage of patients is estimated to be eligible for targeted therapy within the framework of precision cancer medicine, when evaluated with NGS?

Based on the results of the GENIE Consortium Project, what percentage of patients is estimated to be eligible for targeted therapy within the framework of precision cancer medicine, when evaluated with NGS?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Rodrigo Dienstmann, MD

Rodrigo Dienstmann, MD

Principal Investigator, Oncology Data Science (ODysSey) Group
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Computational Oncology Group
Sage Bionetworks
Seattle, Washington, USA